APPENDIX 1 ARIMA step and pulse modelling for number and proportion of pharmacist-prescribed opioid, benzodiazepine and stimulant claims (from January 2019 to Nov 22, 2020)

| Parameter                      | Step Function (April 5, 2020) | Pulse Function (April 5, 2020) |
|-------------------------------|--------------------------------|--------------------------------|
| Number opioid claims          | \( p < 0.0001 \)               | \( p = 0.382 \)               |
| Number BZD* claims            | \( p < 0.0001 \)               | \( p = 0.811 \)               |
| Number stimulant claims       | \( p < 0.0001 \)               | \( p < 0.0001 \)               |
| Proportion opioid claims      | \( p < 0.0001 \)               | \( p = 0.282 \)               |
| Proportion BZD claims         | \( p < 0.0001 \)               | \( p = 0.9258 \)              |
| Proportion stimulant claims   | \( p < 0.0001 \)               | \( p = 0.0001 \)              |

* BZD, benzodiazepine.

Chang A, et al. Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: a cross-sectional time-series analysis. *Can Pharm J (Ott)* 2022;155. DOI: 10.1177/17151635221126481.